Jeff Ryckman: Fascinating results for neoadjuvant Aumolertinib in EGFR-Mutant NSCLC
Jeff Ryckman, Assistant Professor of Radiation Oncology at WVU Medicine Camden Clark Medical Center, shared a post on X by Yakup Ergün, Medical Oncologist at Antalya City Hospital, adding:
“Wow, fascinating results, especially considering neoadjuvant Osimertinib is associated with ~2% pCR (n=1/52) according to two prospective single-arm phase II studies!
Congratulations to the authors!”
Quoting Yakup Ergün’s post, about a paper by Dongliang Bian et al. published in Nature Communications:
“Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant NSCLC.
51 patients
ORR – 70.6% (Beat the 70% goal)
23 patients (45.1%) became operable! R0: 100%, MPR: 21.7%, pCR: 13%
1-yr EFS – 88.2%,
2-yr EFS – 58.8%
G3/4 AE: 9.8%, no G5.”
Authors: Dongliang Bian, Shuyu Ji, Yue Liu, Zhida Huang, Lei Jiang, Chunyan Wu, Deping Zhao, Liang Duan, Gening Jiang, Peng Zhang et al.
More posts featuring Jeff Ryckman and Yakup Ergün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023